

Development status of drugs targeting histone modifications and histone modifiers in oncology			
Research	Preclinical development	Clinical development	Approved
KDMi; KMTi; HATi; HDACi Bromodomain inhibitors; other chromatin readers			
	BETi; EZH2i (CPI-1205); KDMi (KDM5i)		
	BETi (IBET762, CPI-0610, OTX-015, Ten010, RVX-208); EZH2i (EPZ6438, GSK126); LSDi (OG98, GSK2879552, SP2577) DOT1Li (EPZ5676); selective HDACi, DNMTi		
	DNMTi (Azacitidine, Decitabine); HDACi (vorinostat, romidepsin)		

Figure 5. The development status of epigenetic drugs. KDMi, lysine demethylase inhibitor; KMTi, lysine methyltransferase inhibitor; HATi, histone acetyltransferase inhibitor; HDACi, histone deacetylase inhibitor; BETi, bromodomain and extracarboxy terminal domain inhibitor; DNMTi, DNA methyltransferase inhibitor.